– USA, CA – Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases, today announced the appointment of Erik Harris to its Board of Directors.
Mr. Harris’ extensive biotech leadership and pharmaceutical experience includes 20 years in all aspects of commercial operations and achieving successful product launches in multiple therapeutic areas, including neurological and rare diseases.
“I’m excited to welcome Erik to our Board of Directors. Erik’s experience and perspective will be valuable as we now transition to a late-stage development company with a diverse portfolio of therapeutic candidates and continue to build out our commercial capabilities with the goal to ultimately bring medicines to patients with neurodegenerative and lysosomal diseases,” said CEO, Dr. Ryan Watts.
About Erik Harris
Erik Harris currently serves as the Chief Commercial Officer and EVP of Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of a diverse portfolio of therapies for patients with rare and ultra-rare genetic diseases. Mr. Harris joined Ultragenyx in 2017 as SVP and Head of North American Commercial Operations. Earlier in his career, he held positions in the commercial organizations at Crescendo Bioscience, Intermune, Elan Pharmaceuticals, Inc., Genentech, Inc., and Bristol Myers Squibb Company. In addition to the launch of Ultragenyx’s Crysvita, Mepsevii, and Dojolvi, Mr. Harris has been involved in the launches of Tarceva, Tysabri, and Vectra-DA. To begin his professional career, Mr. Harris served as a Lieutenant Commander in Naval Aviation and Congressional Fellow for the United States Navy.
“Denali is making significant progress toward a global organization serving patients with neurodegenerative diseases,” commented Mr. Harris. “I am very excited to join Denali’s Board of Directors. I look forward to contributing to Denali by applying my insights in bringing high-impact, novel medicines to patients and their families.”
Mr. Harris received his Masters of Business Administration at the Wharton School of Business and Bachelor of Science at the United States Naval Academy.
About Denali Therapeutics
Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB, and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco.
For more information: https://www.denalitherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.